First Solar (NASDAQ:FSLR): Home run on loan guarantees - Credit Suisse

The call of the day comes from Credit Suisse Solar team as they comment on First Solar (NASDAQ:FSLR) following an Associated Press report saying the company has won conditional loan guarantees for 3 of their Solar projects.

Here's the link: APNewsbreak: Solar loan guarantees announced

- CSFB is raising their CY11 EPS from $9.00 to $9.68; CY12 EPS goes from $9.92 to $14.03; their CY13 EPS goes from $8 to $12.62; CY14 goes from $3.70 to $9.29.

These are all hefty raises, now way above consensus.

- CSFB is raising their target on FSLR to $135 (prev. $100) noting the stock could over shoot to the $140-$150 level today to reflect longevity of earnings through 2013.

Here are some of the details:

Bottomline – raising estimates and target price. FSLR already had the Agua Caliente conditional loan guarantee in the bag, and had loaded the bases by submitting additional loan guarantees on three other projects to the DOE. Now the company has literally knocked the ball out of the park – with the Associated Press reporting that the DOE is expected to announce on Thursday that $4.5bb in additional conditional guarantees will be issued for FSLR projects.

Details: 1) $680mm for AV solar ranch; 2) $1.88bb for Desert Sunlight; 3) $1.93bb for Topaz. We had noted in several notes in the past, including most recently on Monday, that all three were in the running for a loan guarantee and the DOE had recently likely concluded the credit review of these projects. We had also noted that this week would be crunch time for additional loan guarantees. We were modeling FSLR will get one additional guarantee, but had noted all three projects were in the running. Getting all three additional guarantees is a positive surprise to our expectations, and we are therefore raising our estimates and target price.

The additional longevity of earnings at this high level is a key change in the equation – which could result in the stock trading up to $140-$150 levels. We are therefore using a simple DCF now to arrive at a new price target of $135 on the stock. Eventually the bear thesis will need to revert back to oversupply such that the panel business possibly loses money due to competition – but this is an issue the market may not focus on in the very near term.

Notablecalls: This is easily the most significant piece of Solar news this summer. These FSLR contracts were signed around 2008, which means the terms are very favourable in terms of pricing vs. today. The DOE loan guarantees provide very cheap financing, which further amplifies the profitability of the projects. The upside could be $5-6 in EPS in 2012/13.

Most analysts were expecting 1 or 2 of the projects to get DOE backing but NONE expected a slam-dunk (all 3) decision we got today.

Solar has been extremely out-of-favour sector evidenced by the whopping 46% short interest in FSLR. I would call this an explosive combo.

I expect FSLR to trade $140-145 range today. Yes, I'm expecting a $10-15 pt move.

U.S. Steel (NYSE:X): Deutsche upgrades to Buy; Goldman calls bottom in space

Steel stocks are getting very supportive comments from two tier-1 firms this morning:

- Deutsche Bank is upgrading both U.S. Steel (NYSE:X) and AK Steel (NYSE:AKS) to Buy from Hold with $56 & $17.50 price targets respectively.

Firm notes they could think of many appropriate titles for this report, but in a nutshell, they now view steel dynamics and investor sentiment as nearly the inverse of early 2011 when they downgraded the sector. Their upgrade is largely based on valuation, but they also believe that steel prices are nearing a 'floor'. Buy AKS and X in anticipation of steel price and demand inflection.

Steel correction healthy (necessary) and prices poised to bottom
DB says they viewed the HRC push to $900/st as negative, and reported average prices have declined to $740-750/st. Meanwhile, 'unreported' prices are below $700/st and inline with prior 'correction' expectation. They now forecast that benchmark US HRC prices will average $830/mt in ‘11 ($753/st) and $772/mt in ‘12 ($700/st); increased ~1% vs prior. Also, firm's demand outlook is unchanged as they expected NA growth of 7% and 5% in '11-‘12 and global gains of 8% and 6% respectively. Catalysts: steel prices and apparent consumption; seasonal trade could come earlier than normal

Deutsche believes that steel prices are approaching cost support (marginal cost) and could ultimately push supply out of the market. Scrap prices have been more supportive than expected in recent months and trade contacts suggest that nearterm (ex July) prices will be flat-to-up. Further, downtime announcements are likely forthcoming which they’d view as positive, if weakness persists (add’l declines of $100+/st are possible). Also, global steel prices are to become more supported including in China where they believe inventories and steel prices are near bottom. On demand, they expect the 'buyers strike' to end soon...here they find it interesting that recent conversations with consumers have focused on supply risks and when asked, most contacts recognize that end-demand remains 'ok. Also, they anticipate some improvements in industrial activity in 2H (ex. autos), and net-net, the firm thinks the seasonal steel 'trade' could begin earlier this year.

Valuation: risk-reward more favorable; AKS & X to Buy
DB notes their PTs imply average upside of 27% and steel stocks are near the low-end of trading ranges. AK Steel and US Steel shares are near levels from late ‘10 when US HRC was below $550/st. Also, their EV/t analysis shows that AKS and X are 'cheap' vs peers and historical trends, and their 'what's priced in’ analysis suggests the market is assuming below avg margins - AK appears particularly attractive using this tool. Regarding AK, the firm hasn't recommended it since early ‘10 and it has been a laggard on cost/other concerns.


- Goldman Sachs is out with a Scrap Steel sector call noting their latest channel checks indicate an upward bias (around $20 per ton) for July scrap prices, which is highly unusual considering seasonality and indeed very positive for providing cost support to steel prices. Almost all the input material costs (iron ore, coking coal and scrap) are either stable or rising going into seasonally slow summer months which underscores our view that steel prices could be close to a bottom.

Steel demand could also surprise to the upside in 3Q
Firm notes they had earlier estimated that the industry utilization rate would move close to 80% in seasonally strong spring period and then come down as we head into the summer months. Although this did not occur, they are pleased to see a steady state of demand and utilization rate hovering around 75%. Goldman believes that a typical summer slowdown in demand could be of a much lesser magnitude this year as auto industry is recovering at a rapid pace from the Japanese earthquake related supply chain disruptions.


Mini-mill margins at tipping point; steel prices should see support
Goldman notes that historically they have seen that when steel price reaches close to the cost of the lowest cost producers (mini-mills), it generally signals a bottom. And if there is some support from demand, prices generally bounce back. With expectations of busheling scrap to be around $530 per ton in July, they estimate mini-mill cost at around $680 per ton for HRC. At current level between $700 and $740 per ton, the firm sees very limited room for further degradation in steel prices. Barring any major downward correction in scrap prices in coming months, they believe that steel prices could bottom at above $700 per ton in this cycle, a very positive outcome considering that last year’s bottom was at round $540.


Notablecalls: Deutsche almost caught the recent top with their Steel sector downgrade, so with the firm now turning positive, people will likely take notice.

Regarding Goldman, this is a Scrap Steel call but as many industry watchers probably agree, scrap tends to lead the sector moves. I very much enjoyed reading their mini-mill comments.

So, with two tier-1 firms calling the bottom in Steel names, we can expect a strong upside move in the names today. The whole sector should be up.

My poison of choice is U.S. Steel (NYSE:X) which I think is the best mover in the group. I think the stock can do $45+ today.

Apple (NASDAQ:AAPL): Buy Apple for Summer Rally - Morgan Stanley

Morgan Stanley is making positive Research Tactical Idea call on Apple (NASDAQ:AAPL) this morning calling for a summer rally in the name.

- Deutsche analyst Chris Whitmore is also very positive this morning raising his #'s on AAPL.

Recent dip a buying opportunity. After meetings in Taiwan last week, they expect Apple order cuts to ease and iPhone / iPad production to begin ramping aggressively from August through year-end. Firm views the recent valuation pullback as a buying opportunity in light of the following factors, and issued a Research Tactical Idea on AAPL along with this note.

1) Post-Japan earthquake production constraints have eased, putting upward pressure on iPad shipments.

2) With improved component supply, Apple is negotiating price cuts with some suppliers, potentially boosting margins modestly in the June quarter and more in September.

3) Apple’s next iPhone will begin production in mid to late August and ramp aggressively into C4Q.

Shifting iPhone units into C4Q; CY11 estimates unchanged: To reflect a late C3Q iPhone launch, the firm shifts 2 million units from the September quarter to the December quarter but their full year estimate of 72 million units remain unchanged. An early September iPhone launch would drive upside to their lowered September quarter estimates, in their view.

Lower priced iPhones and TV are additional mid-term catalysts: Apple is forecasting a large iPhone unit increase in CY12 on the back of new products and potentially lower price points. Morgan Stanley also believes Apple is in the early design stages for a TV, which could add $19 billion and $4.50 of annual revenue and EPS longer-term.

- Deutsche Bank is also out positive on Apple this morning saying they expect the co to refresh the iPhone in September with two SKUs; namely the iPhone 5 and a lower-end iPhone 4S handset. With Nokia and RIMM struggling, the time is right for Apple to aggressively penetrate the mid range smart-phone market (i.e. $300-500 category) to dramatically expand its addressable TAM and market share.

Deutsche believes Apple could offer an unlocked iPhone 4S with a prepaid voice offering (parallels the 3G data plan vs. WiFi for iPad) which would drive significantly greater penetration into its 1.5B+ subscriber reach (2/3 are pre-paid) through 200+ carriers in 98 countries. They estimate an iPhone 4S model priced at $349 would likely be incremental to Apple’s corporate gross margin suggesting it can push down-market without negatively impacting profitability. The firm also believes near term iPhone 4 demand is tracking ahead of their previous expectation due to: the addition of 20+ new carriers in the Q, strong white iPhone uptake and wider global distribution.

Deutsche believes Apple’s international channel and related penetration opportunities are under appreciated and are raising iPhone and EPS estimates (DB at 74M iPhones in CY11 and 90M in CY12 vs. prior 71M and 85M, respectively). Although they expect Apple to move more aggressively into the midrange smartphone market, it is not currently captured in these estimates. Looking forward, they expect the upcoming iPhone / iOS upgrade and channel/carrier expansion to support strong iPhone demand over multiple quarters. Firm reiterates their Buy rating and $450 PT.

Notablecalls: It is certainly interesting to see two tier-1 firms out quite positive on Apple after a period of cautious-sounding data points. Needless to say, both are known bulls in the name.

Morgan Stanley has given their analyst teams a way to make shorter-term calls, called Research Tactical Ideas (RTI). For example, in AAPL's case they are calling for the stock to trade up in the next 60 days, giving this view a 70-80% or very likely probability of happening. That's a fairly bold statement & should generate some interest.

Also notice how the analyst is embracing the possibility of an Apple TV.

There are two interesting bits of info in the Deutsche call:

1) DBAB is calling for both unlocked iPhone 4S & a brand new iPhone 5. Lately, the consensus has shifted towards the view that there will be no lower-end iPhone. So there could be some upside there.

2) The firm is raising their iPhone ests for 2011 to 74M, which is actually above Morgan Stanley. I'm sure many of you know Morgan Stanley has been THE iPhone bull.

I think there could be some n-t upside in AAPL. RTI's usually generate immediate buy interest, so barring a market crash, the stock could be on the way up today.

I'm thinking $332+

Feedback appreciated.

United Continental (NYSE:UAL): Watch the Airlines in the n-t

I think traders should keep the Airline names on their radar this morning after United Continental (NYSE:UAL) reported weaker-than-expected RASM #'s last night.

here's the link to the PR

Here are some comments from tier-1 firms this morning:

UBS: United’s implied June revenue guidance was below expectations and when combined with other guidance suggests Q2 consensus EPS numbers are about $0.30 too high. Tomorrow will likely be a bad day for the airline stocks after a good, oil-driven day today. Given United’s June revenue, Delta’s double digit RASM growth guidance for Q2 looks very challenging.

Our 12-month PT falls to $36 from $39 based on ~6x EV/EBITDAR. Our 2011 EPS est. drops to $4.00 from $4.42. Maintains Buy.

Morgan Stanley: UAL guided to 2Q11 PRASM growth of ~8.8%, below sell-side ests. for 10%-11%. Though it was clear June PRASM growth would be lower than UAL’s ~14.5% May result, guid. implies June growth of 4%-5%, below our est. of a high-single digit result. Despite ~6pts of one-time adjustments in June, we believe UAL’s outlook will negatively impact investor sentiment as it will fuel demand risk concerns. That said, given low valuations, the recent selloff, and the demand skepticism we have heard from investors of late, we believe investors’ ests. were below the sell-side, which should dampen the neg. reaction. Furthermore, the possibility of stronger results from UAL’s legacy peers remains a potential positive catalyst.

(It's also worth noting MSCO is closing their positive Research Tactical Ideas on LCC & DAL, due to UAL news)


Barclays: June RASM from UAL was a disappointment. We underestimated revenue reconciliation payments UAL would have to make to alliance partners at quarter’s end, but we still find performance a bit disappointing. Our forward estimates reflect revenue deceleration on declining fuel and a recent softer economic climate. We now believe that deceleration developed earlier than expected, though recent feedback from DAL suggests less deceleration. We expect UAL and the group to be soft on the heels of this announcement, but at earnings multiples in the low single digits we would be buyers of material weakness, especially in UAL and DAL

Deutsche: We are lowering our June Q diluted EPS estimate for UAL from $1.75 to $1.50 (vs. consensus of $1.60) - a reversal of a change we made three weeks ago - as PRASM for the month of June came in lighter-than-expected (e.g. mid-single digit PRASM gain). We were expecting a 12% gain in PRASM for the month of June; based on quarterly guidance issued by the company last night, we estimate the gain to be closer to 5%. Also, we are lowering our full year 2011 EPS estimate from $3.35 to $3.10 (vs. consensus of $3.83).

Overall, no change to our longer-term investment case for Buy-rated UAL. Furthermore, the stock is fairly inexpensive on our more conservative forecast as its enterprise value is currently trading at 5.0x and 4.8x our 2011 and 2012 EBITDAR forecasts, respectively. As such, should the stock be under pressure this morning, we would see it as an opportunity for investors to add to their position.

Notablecalls: While not a disaster, UAL's #'s tell a story of possible deceleration in the sector. It looks like the group has been reluctant to move higher even in face of significantly declining oil price. Now that we have bad news, it appears the group is vulnerable to the downside. Analyst consensus clearly stands too high.

While total gambling on my part, it LOOKS LIKE oil is getting ready for a bounce today. That should add some fuel to the fire.

I haven't received anything from J.P Morgan's Airline God Mr. Baker this morning, so he must still be positive on the group.

I'm thinking UAL will be down 5%+ today. Maybe there's a trade there.


PS: I'm posting this on market open.

Advanced Micro Devices (NYSE:AMD): BREAKING NEWS - CEO FROM IBM

Advanced Micro Devices (NYSE:AMD) may have major news, possibly as soon as today:

Bright Side of News reports: The next CEO of AMD comes from IBM

Quote: While we are not in the liberty of disclosing the name of the new CEO (if the person in question signs that contract), the negotiations did not took a long time and are being finalized as I write these lines.

If the contract gets signed this or next week, expect to see the announcement coming before AMD posts its second quarter results - expected to take place on July 21, 2011 at 2PM Pacific/5PM Eastern.

Here's what the analysts have been saying past month or so:

Bernstein, June 7: This is one more potential 2H catalyst that could positively impact AMD's shares, coming on top of the launch of Llano and Bulldozer, and (hopefully) the arrival of a new CEO.

UBS, June 10: New AMD CEO has significant opportunity and challenges We believe a new CEO appointment could occur within the next 2 months, which could be a catalyst for the stock, especially given attractive valuation, as it removes a major source of ongoing uncertainty. To sustain any near-term rise, we believe the new CEO needs to tackle 7 strategic issues with servers as the most important in our opinion, followed by disciplined execution on the APU strategy. We remain Neutral given execution risks and at least until the new CEO articulates his vision.

FBR, June 16: We still have concerns about AMD’s lack of strategy (tablets and mobile) and leadership, though a new CEO hire could drive shares higher, depending upon the person. We are raising our rating on AMD from MP to OP and our target from $10 to $12, based on a higher 15x target P/ E multiple (including stock compensation, excluding net debt and interest expense).


Notablecalls: AMD stock is down 25% in the past month or so underperforming even its larger peer INTC. And now we have news out saying their new CEO is coming from IBM.

I think one couldn't ask for a better hire. IBM grooms the best of breed technology execs that can adapt to any business environment. This is what AMD needs. This is what the analysts have dreamed of.

I expect AMD to trade up markedly today, once the news gets out. AMD up 5-7%+ today? Am I too optimistic?

Home Health: Downgrading Sector View; Cutting Estimates; See More Downside - Baird

Baird's Health Care team is downgrading Home Health Sector to Underperform this morning saying they would not buy any home health stocks and expect the tape/news flow to get worse. Furthermore, 2012 estimates look to be 20%-30% too high, multiples stretched relative to the 2-3 year trading range and in general, the group looks vulnerable. Admittedly, sentiment is horrible, but we think it gets much worse before better, expect 2Q misses, lowered guidance, a very negative CMS proposal (will surprise many) and increasingly worry about the sector's exposure as a doc-fix/debt ceiling pay-for.

- AFAM cut to Underperform, $21 target (prev. $32)

- LHCG cut to Underperform, $17 target (prev. 27)

- GTIV cut to Neutral, $23 target (prev. $35)

- AMED target is cut to $26 (prev $35)


The details:

This is not a negative "call" on known issues of the F2F reg, but rather: 1) issues stemming from documentation which will lead to higher bad debt reserves, 2) we see significant risks in the upcoming CMS proposal and 3) valuations look stretched, we do not believe M&A is coming and the group is very vulnerable as doc-fix/debt ceiling pay-for.

Street too complacent on 2012 CMS proposal. We are struck with the large number of investors who do not see the risks to the 2012 coding creep. Our DC lobby contacts struggle to see any scenario in which the -3.79% coding creep does not grow and/or potentially point to future reductions. CMS will absolutely consider 2009 "coding" in the 2012 rule. Both our outside consultant and the industry's lobby believe CMS has identified ~3.3% of "increased coding" from 2008-2009. Thus, if CMS does not spread out cuts ('11 reg said they wouldn't), we could easily see a ~7% case-mix adjustment. Our revised 2012 numbers assume a 5% rate cut, which we believe is not aggressive.

Based on our recent conversations with many private companies and industry contacts, we believe the industry on average is struggling to obtain proper documentation for approximately 10%-25% (in some cases much more depending on what month) of home health SOCs (starts-of-care; e.g., admissions). Ironically, the Street has obsessed about the "volume" impact from patients that potentially would not meet the 90 days prior to or 30 days after rule, but based on multiple conversations with our network of industry participants, we have uncovered a substantial problem in obtaining the "proper" documentation from patients that actually meet the 5 requirements of the reg. As a result, we understand some providers may book ~100 bps of additional bad debt expense to account for the uncertainties related to obtaining F2F documentation for these patients (i.e., the "collectability" of these revenues). We do not believe investors are aware of this issue and it could pressure 2Q and 2H11 results.

Lowering estimates, group looks vulnerable. Our 2012 EPS estimates are now 20%-30% below the Street. We firmly believe the CMS proposal surprises on the downside probably in mid-July, which is before earnings. We expect all providers to likely miss and lower not just for the F2F "volume" impact, but due to higher reserves as providers are struggling to get documentation for patients that meet the encounter requirement. Home health stocks likely oscillate near 10x earnings (we fear could be worse as HH is likely to be included in the doc-fix/debt ceiling), thus we worry about another 20%-30% sell-off in the coming months. With this research note, we are revising our sector suitability rating to Higher Risk.

Notablecalls: This is going to hurt. Looks like Baird has done some real digging and uncovered additional problems in the sector. Many of the names appear cheap on surface but if one adjusts for the new info from Baird, they suddenly don't look that cheap anymore. It's been a tainted sector for a while.

This is a fundamental call & although many of the names carry hefty short interest I expect 5-7% downside moves in LHCG & AFAM.

GTIV and AMED will also get hit but less so.

Molycorp (NYSE:MCP): Bounce?

Molycorp (NYSE:MCP) is getting bumped at two firms this morning:

- J.P. Morgan is out with a very positive note raising their estimates and price target on the Rare Earths miner. Firm's new price tag is $105 (prev. $87) to reflect the continued rise in rare earth prices and their belief that MCP can operate significantly below its planned capacity and still realize sharp increases in shareholder value.

In fact, the firm estimates MCP could operate at 50% of capacity and see current spot prices drop 40% and still generate an NPV of $105/share. They think the stock will start to move higher as four misconceptions about MCP and the sector are ultimately dispelled: 1) MCP is struggling to achieve market prices, 2) ramping production from MCP will bring on too much supply post 2014, 3) China will ultimately reverse its production and export tightening measures, and 4) new supply outside of China will chase prices and eventually bring on too much supply.

Raising EPS. JPM is raising their EPS estimates (2012 to $5.93 from $5.25, 2013 to $14.48 from $12.51, and 2014 to $27.01 from $22.45) to reflect the continued increase in rare earth prices. In just the last month, average oxide export prices are up 22% and 195% YTD. In China over the last month, average domestic oxide prices are up 81% and 472% YTD.


- Piper Jaffray is upgrading MCP to Overweight from Neutral with a $73 price target (unch) following the stock's ~40% correction since early May.

Piper believes the pullback overly discounts the risk that rare earth prices will fall precipitously – which they believe is unlikely to occur over the next 6-12 months. They maintain their $73 price target and view continued restrictive policy actions from China, positive 2Q results, and progress on the funded capital project as potential catalysts for the stock. Less conservative pricing assumptions in our model could present upside north of $100/share.

Recent pullback creates an attractive entry point. MCP remains a highly controversial stock, fueled by the sharp run-up in rare earth pricing over the past year and uncertainty around Chinese policy on quotas and tariffs. Piper fully expects rare earth prices to fall in the future as additional supply comes online – they have incorporated an average price reduction of 60% by 2013 in their model – but looking out over the next 6-12 months, they see little change to industry fundamentals. At current valuations, they believe the market is pricing in 1) more severe price cuts in the 70%+ range AND 2) no additional volume from Phase II of the company's project plan which will double production capacity in 2014. Piper believes these assumptions are overly pessimistic in at least the near term.

Near-term catalysts present potential for upside. In the next several weeks, China will unveil its quota policy for 2H11. They expect the rare earth quota level for 2H11 to be set consistent with 1H11 levels, which will continue to strain global supply. Piper believes the release of the quota policy will once again revive fears of China's restrictive policies on rare earths, which will support near-term pricing. Additionally, they believe MCP is poised to report strong 2Q results with production levels showing a healthy q/q increase and pricing expectations on Lanthanum have been set more appropriately following the 1Q confusion.

Notablecalls: I think these calls serve to push MCP higher in the n-t. The stock is down 30 pts from its highs and ripe for a nice juicy bounce.

Short interest stands at close to 20%.

I would suggest you take a look at other Rare Earths names as well, namely Avalon (AMEX:AVL) & possibly Rare Elements (AMEX:REE) as the calls are likely to create buy interest in the whole space.

I'm thinking MCP can generate 7-10% upside. Am I too optimistic?


PS: I personally think none of these analysts have any credible insight into what's really going on in China. So this is just a sentiment trade.

Novatel Wireless (NASDAQ:NVTL): Actionable Call Alert!

BMO Capital Markets analyst Tim Long is making a potentially a very significant call on Novatel Wireless (NASDAQ:NVTL) saying business at Verizon is accelerating markedly.

- This is likely to result in way higher-than-consensus #'s. Firm rates their Outperform rating and $12 target.

A recent round of checks on LTE MiFi sell-through at Verizon has been positive. BMO believes Novatel’s MiFi has emerged as the preferred LTE device in their checks. Verizon appears to have stopped selling CDMA modems and hotspots in all markets, and this alone should increase NVTL’s ASPs and revenues. Firm estimates that a normal handset upgrade rate woul dresult in significantly higher revenues than their above-consensus estimates. BMO estimates upgrading Verizon’s existing 6 million Mobile Broadband Subsis worth more than $1B in device revenue. They are above consensus for both3Q and 4Q as they think the Street underestimates the impact of higher ASPs,a return to a normal upgrade rate and the expanding addressable market. They also believe that embedded revenues will start ramping and that Novatel and Sierra could take 50% of the embedded laptop/netbook market.

Channel Checks
Checks with Verizon stores in several cities since the launch of the Novatel LTE MiFi in late April indicate that it is selling well. Several store reps BMO talked with discussed selling at least one MiFi per day and all reported a significant increase over prior quarters. Almost all of the store reps they talked with are pushing the Novatel MiFi over the Samsung hotspot owing to performance issues with the Samsung device, Novatel’s MiFi brand, and better form factor. These sentiments were echoed at the Verizon website where reviews of the Samsung device were overwhelming negative. Many reviewers received several replacement Samsung devices before switching to the MiFi, which they had no issues with. BMO also expects the Novatel LTE USB modem to become available in Verizon retail stores shortly, as the LTE-only LG modem has been discontinued. Previously the Novatel modem was available only on line. They believe that Verizon is upgrading existing CDMA mobile broadband customers for free, even for customers who bought a CDMA MiFi within the past several months.

VZ Revenue Assumptions Likely Conservative
BMO models Verizon’s mobile broadband subs, upgrade rate, net adds (which it recently began reporting) ASPs, market share and dongle/MiFi mix to estimate Novatel revenues at Verizon. Firm's base case assumes that net adds slow to 300,000 per quarter, upgrade rate increases to 9%, NVTL has 75% share of MBB at Verizon, MiFi is 70% of the mix, and ASPs decline by 2% per quarter. These assumptions result in 2011/2012 revenues of $348 million/$504 million, basically double the current estimates in their model of $186 million and $200 million.

Where Their Call Differs
BMO notes they are one of only two positive ratings on the stock. Firm believes their estimates are the most detailed, as we model the company at a carrier level, looking at both units and ASP. The stock has been out of favor for a while. The last major technology upgrade cycle began eight years ago, MiFi didn’t live up to the initial hype, Asian competitors took share worldwide, and Qualcomm had taken 95% of the embedded laptop business. They think that the Mobile Broadband business, while it tends to be a bit choppier than M2M, has much better leverage and better economies of scale to create value for companies that do it well.

BMO believes the Street is modeling one quarter of strength from LTE. They, however, think there will be several strong quarters. As a result, their September revenue estimate of $142 million is well above consensus of $119 million. They are also way above for 2012 revenues and earnings.

Valuation
The P/E ratio of NVTL has varied considerably owing to the inherent leverage in the model, with P/Es in excess of 70x prior to the launch of EVDO rev A. Therefore, BMO believes EV/sales is a better comparison when looking at historic valuation. BMO's $12 price target for NVTL implies a P/E of 12x their 2012 pro forma EPS estimate and an EV/Sales of about 0.5, below the 2007 ratio of 1.2.

Notablecalls: Well guys, this is potentially a game-changing call from BMO. NVTL has been left for dead as the M2M hype didn't materialize fast enough. Remember NVTL & SWIR were all the rage back in 2007.

Now 4 yrs later Verizon the nations largest wireless operator is starting to push Novatel's Mifi in a major way. It looks like only BMO has picked this up so far, offering investors a potentially huge risk/reward situation.

Even if BMO's half-right, this thing is likely 2x undervalued.

From trading perspective I've witnessed 10-20% intraday moves in NVTL in reaction to positive news. I think we may have similar potential here in the n-t.

I'm fairly sure it can do $5.50 today but I'm certainly hoping for more.

Actionable Call Alert!


PS: I'm intentionally posting this after market open (9:30 ET AM) after watching so many of the small-cap names being bid up to unhealthy levels in the pre-market.

Chelsea Therapeutics (NASDAQ:CHTP): An Orphan Likely To Be Adopted Soon; $18 target - Roth

Roth Capital's David Moskowitz, RPh. is making an interesting call on Chelsea Therapeutics (NASDAQ:CHTP) raising his target on the small-cap biotech to $18 (up from $6).

- It looks like CHTP has significant catalysts ahead.

Here are some excerpts from the call (15pg):

* Strong Buzz On Northera At the Movement Disorder Society (MDS) Conference. On Wednesday and Thursday this week, the company featured several data presentations at the MDS conference in Toronto, Canada, including posters on additional data from Northera’s 306A study, and a subset analysis of multiple systems atrophy (MSA) patients from the drug’s pivotal 301 and 302 trials. Additionally, three presentations as part of the company’s symposium on the “Treatment of NOH in Primary Autonomic Failure with Droxidopa” featured Northera and key data from the 301 and 306A studies solidifying the drug’s broad based efficacy across multiple endpoints in NOH patients, as well as its very favorable safety and tolerability profiles. Importantly, key opinion leaders in the U.S. are awaiting access to the first drug to demonstrate clinical benefits in treating patients with neurogenic orthostatic hypotension (NOH), a major issue in patients with Parkinson’s disease. In fact, Japanese physicians that already have access to the product (marketed by Dainippon Sumitomo in Japan since 1989) expressed significant interest in the new data on the drug presented by Chelsea at the conference. Despite the Northera symposium occurring on the last day of the MDS conference, the presentation room was full, and notably, there was significant activity at the company’s poster sessions the day prior. Many physicians indicated that the striking reduction in falls in Northera-treated patients is a key benefit of the drug candidate. With an estimated 1 million PD patients in the U.S. alone, and up to one-third having symptomatic NOH, we believe Northera has the ability to be a sizable product, despite the intent on initially commercializing the product in an Orphan Drug population (NOH associated with PD).

* We believe Northera’s regulatory package is compelling and supports approval in the neurogenic orthostatic hypotension (NOH) indication. CHTP is in position to gain approval as early as 1Q'12. We raise our PT on CHTP, on increased confidence in the drug’s potential for approval and market opportunity. Data from the recent MDS meeting add support to our investment conclusion.

Summary & Investment Thesis

CHTP’s lead product candidate, Northera (droxidopa), is being readied for a 3Q 2011 submission to the FDA for review, and we believe this drug offers an important benefit to patients with neurogenic orthostatic hypotension (NOH) associated with Parkinson’s Disease (PD). NOH is a disorder caused by a deficient release of norepinephrine, which leads to decreased blood pressure upon standing, lightheadedness, dizziness, blurred vision, and syncope (fainting). In many cases, patients that have NOH can fall and worsen their health status, and in some patients, the disease itself is so debilitating that those patients remain bedridden. As a result, the FDA deems NOH an unmet medical need, and has also granted the company Orphan Drug designation for Northera. As a result, the likelihood of a Priority Review by U.S. regulators could result in a potential FDA approval of the drug in 1Q 2012. We believe the company’s clinical data package for Northera is very strong, given one highly statistically significant Phase III trial (conducted under an SPA), and another Phase III trial that provides highly consistent support to results from the larger study. Because the second study did not achieve statistical significance on the primary endpoint, many investors have exited the shares since the early part of this year, creating an opportunity, in our view. After analyzing the trial data, we believe the second study demonstrates strong efficacy of the drug, given the statistically significant result on the same endpoint as in the first trial (although not prospectively designed as the primary endpoint). Importantly, when pooling the two Phase III trials together (which we believe the FDA will do), the statistical power increases dramatically, and causes the full data set to become highly statistically significant. The compelling Phase III data, the vast efficacy and safety database generated on Northera (the drug has been on the market in Japan since 1989), as well as the high need for the drug in PD patients, boost our confidence that FDA will approve the drug next year, and that sales could peak at over $400 million in the U.S. alone. Given this potentially large opportunity, and that the company has the ability to market the drug with its own small sales force, we believe the financial leverage to the company could be impressive if Northera is approved. As a result, we believe the risk reward on shares of CHTP is compelling and we recommend that event-drive investors with a high-risk tolerance buy the stock.

Notablecalls: While I'm not familiar with CHTP story, I do like what I see so far:

- As per Roth, Docs seem to be really excited about Northera's promise. This has proven to be a significant tell in past cases.

- The company seems to be REALLY close to commercial success as approval is expected some time in 2012. They have orphan status, fast-track & a SPA. Pretty much means they will get priority review.

- Northera has been marketed in Japan since 1989, which means there's a safety database generated over 20 yrs. That resonates well with the FDA.

- There is currently only one alternative treatment on the market (and it could be pulled, according to Roth).

I'm sure there's a catch there somewhere. After all, this is a $250 million biotech. But considering Roth's target is by way the new Street high target for the name and the fact it has produced 25-50% intraday moves in the past, its worth keeping on the radar.

This one could easily trade to $5+ today.

PS: Amazingly, Roth was not involved in CHTP's last equity offering. Deutsche Bank handled the deal in Feb.

ARM Holdings (NASDAQ:ARMH) - Did it work?

The ARM Holdings (NASDAQ:ARMH) call begs the question - Did it work?

Well, sort of. If you look at the squeeze that happened after 9:30 AM ET it clearly didn't. Most likely one would have taken a $0.50 loss on the position.


Yet, if you look at what happened in the pre-market, depending on one's entry/exit a $0.50- 0.80 profit was to be had.

I think what one has to consider is that ARMH is an ADR (American Depository Share), which means it trades primarily elsewhere. ADR's tend to make their moves in the pre-market. There are exceptions of course, one being Nokia (NYSE:NOK). NOK tends to extend its pre-market moves in regular hours.

Just wanted to get this off my chest.

PS: Sorry for the lack of posts lately. I don't want to post stuff for the sake of posting. Posts generate traffic but as many of you know, I don't ride that way. No popularity contests here.

ARM Holdings (NASDAQ:ARMH): Intel plotting a coup at Apple? - Citi

Citigroup Semiconductor team is out with some fairly interesting comments on Apple (NASDAQ:AAPL) & Intel (NASDAQ:INTC) saying a foundry relationship may be forming between the two companies.

Firm's discussions with the hardware supply chain tend to support this belief. Intel has previously acknowledged they would be amenable to such a relationship, under the right conditions. Citi notes they suspect one such condition includes the potential for Apple to eventually convert from an ARM-based core for handsets and tablets to x86. Given the growth opportunity this opens for x86 processors, they would view such a foundry relationship, were it to happen, positively.

Potential to Migrate Apple to x86 — Intel’s revolutionary 22nm multi-gate manufacturing process is likely the main attraction for Apple. While they do expect TSMC to garner a portion of Apple’s foundry business, Intel’s substantial manufacturing lead with such a critical technology makes them a logical candidate. This is especially so given design difficulties Apple may encounter when migrating the Ax processor to 28nm and below. Citi suspects Intel’s late migration of Atom to 22nm could be in relationship to a potential foundry partnership with Apple (much like Samsung’s delay of their Hummingbird solution).

14nm the Trigger Point — Should such a deal materialize, Citi expects Intel will initially produce ARM-based solutions for Apple at 22nm. With an ARM-architect license, they see no hurdles to this. But as Intel readies 14nm (2013), potential for a shift to x86 exists. At that stage, Intel would have appropriately moved along the SOC learning curve. We believe Intel’s recent cap-ex increase, geared predominantly for 14nm, may have been inspired by the potential for an Apple relationship. Recall Intel is building a new fab in Arizona (Fab 42), geared specifically for 14nm.


- ... the note goes on discussing GM impact and current trends. Yada-yada.

Notablecalls: Nothing new about the AAPL/INTC foundy talk. This has been around for a while now. What's significant are the comments regarding AAPL converting their ARM-based core for handsets and tablets to x86.

That would present a major blow for ARM Holdings (NASDAQ:AMRH). The stock is trading up in the pre market (trades primarly in London) but as the Citi comments start circulating, I suspect we will see some selling pressure in the name today.

Chipotle Mexican Grill (NYSE:CMG): A $1,000+ Stock? - Janney

Janney is making Glory Hound call on Chipotle Mexican Grill (NYSE:CMG) calling it a $1,000+ stock in the long-run.

(Got your attention, didn't I?)

Well, their actual 12-month target is a mere Street high of $375 (prev. $330) as their estimates for 2011/12 move above consensus.

The details:

Based on favorable feedback from multiple industry sources, we raise our 2011 and 2012 EPS estimates for Chipotle Mexican Grill (CMG $289.54; Buy) by nine cents and 35 cents, respectively, to $6.85 and $8.45. Each of these figures lies four cents above First Call consensus.

Looking specifically at Q2 2011, we take up our same-store sales forecast to 8.5% from 6.5%, above the Consensus Metrix figure of 7.8%. This drives our Q2 EPS estimate upwards by two cents, to $1.72 (four cents above First Call consensus).

Over time, we view the long-term potential of the Chipotle concept as 3,000-4,000 in the U.S., at least 2,400 in Europe, and at least several hundred in the Asia/Pacific region. This is at least 6,000 worldwide outlets for the Chipotle concept. But we do not believe Chipotle views itself as “just” a burrito company. Indeed, the first of the company’s ShopHouse Southeast Asian Kitchen restaurants is scheduled to open this summer in Washington D.C. Over the long run, it’s entirely possible that the company could host 3-5 concepts under its belt -- each focused on high-quality ingredients, fine-dining cooking techniques, and speedy customer service (albeit through different cuisines).

If -- if -- Chipotle can reasonably keep up its unit growth rate by decade’s end, then the range of P/E multiples we apply to the 2020E EPS range of possibilities (from $30.00 to $45.00) is from 20x to 30x. This sensitivity analysis suggests a year-end 2020 stock price of $600 to $1,350, with the middle portion of our assumptions getting us to a year-end 2020 stock price of $788 to $1,100. Discounting the possible year-end 2020 stock price back to today at a 10.0% discount rate generates a fair value estimate today ranging from $254 to $573. This middle portion of our assumptions, discounted back at a 10.0% rate, provides us with a possible fair value estimate between $334 to $467. With this note, we officially update our fair value estimate to $375 from $330, which is in the lower half of this middle portion of our sensitivity analysis.

Fantasizing about a best-case “what if?” scenario, the table above also includes a (very) long-term unit count potential of 10,000 restaurants, generating an average $2.7 million in annual sales, and a company-level operating margin of 20.0%. This suggests a (very) long-term EPS of over $111.

Dare to dream!

Chipotle Mexican Grill remains our top restaurant-stock pick for 2011, and we reiterate our Buy rating on it.

Notablecalls: It's not every day you see such targets (even the l-t kind) coming from from a sell side shop.

Janney has played their hand in CMG pretty well, keeping their cool while others have downgraded the name due to high valuation and whatnot.

I suspect the $1,000+ target will create some excitement among investors and traders in the n-t.